## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11638253/publications.pdf

Version: 2024-02-01

78	3,149	24	53
papers	citations	h-index	g-index
79	79	79	2471
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	High Burden of Cryptococcal Meningitis Among Antiretroviral Therapy–Experienced Human Immunodeficiency Virus–Infected Patients in Northern Uganda in the Era of "Test and Treatâ€! Implications for Cryptococcal Screening Programs. Open Forum Infectious Diseases, 2022, 9, ofac004.	0.4	9
2	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. New England Journal of Medicine, 2022, 386, 1109-1120.	13.9	119
3	Cerebrospinal Fluid Lactate as a Prognostic Marker of Disease Severity and Mortality in Cryptococcal Meningitis. Clinical Infectious Diseases, 2021, 73, e3077-e3082.	2.9	11
4	Evaluation of the Dynamiker Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of HIV-Associated Cryptococcosis. Journal of Clinical Microbiology, 2021, 59, .	1.8	16
5	A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis. AIDS Research and Human Retroviruses, 2021, 37, 529-533.	0.5	1
6	ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC50. Frontiers in Cellular and Infection Microbiology, 2021, 11, 695240.	1.8	5
7	Evaluation of the Diagnostic Performance of a Semiquantitative Cryptococcal Antigen Point-of-Care Assay among HIV-Infected Persons with Cryptococcal Meningitis. Journal of Clinical Microbiology, 2021, 59, e0086021.	1.8	10
8	Evaluation of the BioFire® FilmArray® Meningitis/Encephalitis panel in an adult and pediatric Ugandan population. Journal De Mycologie Medicale, 2021, 31, 101170.	0.7	15
9	Impact of biological sex on cryptococcal meningitis mortality in Uganda and South Africa. Medical Mycology, 2021, 59, 712-719.	0.3	3
10	Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management. Medical Mycology, 2020, 58, 282-292.	0.3	10
11	Cytomegalovirus Viremia Associated With Increased Mortality in Cryptococcal Meningitis in Sub-Saharan Africa. Clinical Infectious Diseases, 2020, 71, 525-531.	2.9	20
12	Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy–Experienced Ugandans With Virologic Failure. Clinical Infectious Diseases, 2020, 71, 1726-1731.	2.9	15
13	Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials. Clinical Infectious Diseases, 2020, 71, e45-e49.	2.9	17
14	Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Diseases, The, 2020, 20, 308-317.	4.6	80
15	Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	35
16	A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. Aids, 2020, 34, 1425-1428.	1.0	9
17	Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda. BMC Infectious Diseases, 2020, 20, 572.	1.3	7
18	Impact of community engagement and social support on the outcomes of HIV-related meningitis clinical trials in a resource-limited setting. Research Involvement and Engagement, 2020, 6, 49.	1.1	3

#	Article	IF	CITATIONS
19	Standardized Urine-Based Tuberculosis (TB) Screening With TB-Lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan Adults With Advanced Human Immunodeficiency Virus Disease and Suspected Meningitis. Open Forum Infectious Diseases, 2020, 7, ofaa100.	0.4	21
20	Tuberculosis in HIV-Associated Cryptococcal Meningitis is Associated with an Increased Risk of Death. Journal of Clinical Medicine, 2020, 9, 781.	1.0	12
21	"False negative―CSF cryptococcal antigen with clinical meningitis: Case reports and review of literature. Medical Mycology Case Reports, 2020, 29, 29-31.	0.7	11
22	Evaluation of Serum Cryptococcal Antigen Testing Using Two Novel Semiquantitative Lateral Flow Assays in Persons with Cryptococcal Antigenemia. Journal of Clinical Microbiology, 2020, 58, .	1.8	25
23	Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis. Open Forum Infectious Diseases, 2020, 7, ofaa530.	0.4	3
24	Minimum Inhibitory Concentration Distribution of Fluconazole Against Cryptococcus Species and the Fluconazole Exposure Prediction Model. Open Forum Infectious Diseases, 2019, 6, .	0.4	17
25	Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infectious Diseases, The, 2019, 19, 843-851.	4.6	92
26	Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study. BMC Infectious Diseases, 2019, 19, 558.	1.3	7
27	Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 565-576.	0.8	3
28	Shortâ€course amphotericin B in addition to sertraline and fluconazole for treatment of HIVâ€associated cryptococcal meningitis in rural Tanzania. Mycoses, 2019, 62, 1127-1132.	1.8	13
29	The Changing Epidemiology of HIV-Associated Adult Meningitis, Uganda 2015–2017. Open Forum Infectious Diseases, 2019, 6, ofz419.	0.4	38
30	Culture-negative cryptococcal meningitis. Lancet Infectious Diseases, The, 2019, 19, 929-930.	4.6	3
31	The conundrum of clinical trials and standard of care in sub-Saharan Africa – the research nurse perspective. Journal of Research in Nursing, 2019, 24, 649-660.	0.3	10
32	HIV-Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts. Journal of Infectious Diseases, 2019, 219, 877-883.	1.9	43
33	Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis. Clinical Infectious Diseases, 2019, 68, 2094-2098.	2.9	33
34	Seizures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Predictors and Outcomes. Open Forum Infectious Diseases, 2019, 6, ofz478.	0.4	15
35	Performance of Lipoarabinomannan Assay using Cerebrospinal fluid for the diagnosis of Tuberculous meningitis among HIV patients. Wellcome Open Research, 2019, 4, 123.	0.9	8
36	Performance of Lipoarabinomannan Assay using Cerebrospinal fluid for the diagnosis of Tuberculous meningitis among HIV patients. Wellcome Open Research, 2019, 4, 123.	0.9	12

#	Article	IF	Citations
37	Cryptococcal Disease in the Era of $\hat{a} \in \infty$ Test and Treat $\hat{a} \in \mathbb{R}$ Is There Cause for Concern?. Open Forum Infectious Diseases, 2018, 5, of x274.	0.4	9
38	Evaluation of trypan blue stain in the TC20 automated cell counter as a point-of-care for the enumeration of viable cryptococcal cells in cerebrospinal fluid. Medical Mycology, 2018, 56, 559-564.	0.3	5
39	Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases, The, 2018, 18, 68-75.	4.6	240
40	Blood neutrophil counts in HIV-infected patients with cryptococcal meningitis: Association with mortality. PLoS ONE, 2018, 13, e0209337.	1,1	18
41	Cryptococcal Meningitis and Tuberculous Meningitis Co-infection in HIV-Infected Ugandan Adults. Open Forum Infectious Diseases, 2018, 5, ofy193.	0.4	23
42	Cerebral Oximetry for Detecting High-mortality Risk Patients with Cryptococcal Meningitis. Open Forum Infectious Diseases, 2018, 5, ofy105.	0.4	11
43	Delta-like 1 protein, vitamin D binding protein and fetuin for detection of Mycobacterium tuberculosismeningitis. Biomarkers in Medicine, 2018, 12, 707-716.	0.6	21
44	Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation. Open Forum Infectious Diseases, 2018, 5, ofy122.	0.4	44
45	Tuberculous meningitis diagnosis and outcomes during the Xpert MTB/Rif era: a 6.5-year cohort study in Uganda. Wellcome Open Research, 2018, 3, 64.	0.9	20
46	Ophthalmic signs in Ugandan adults with HIV-associated cryptococcal meningitis: A nested analysis of the ASTRO-CM cohort. Wellcome Open Research, 2018, 3, 80.	0.9	4
47	Evaluation of a point-of-care immunoassay test kit â€~StrongStep' for cryptococcal antigen detection. PLoS ONE, 2018, 13, e0190652.	1.1	22
48	Ophthalmic signs in Ugandan adults with HIV-associated cryptococcal meningitis: A nested analysis of the ASTRO-CM cohort. Wellcome Open Research, 2018, 3, 80.	0.9	3
49	Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings. Expert Review of Anti-Infective Therapy, 2017, 15, 331-340.	2.0	13
50	Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis. Journal of Infectious Diseases, 2017, 215, 693-697.	1.9	20
51	Acute Kidney Injury and Urinary Biomarkers in Human Immunodeficiency Virus–Associated Cryptococcal Meningitis. Open Forum Infectious Diseases, 2017, 4, ofx127.	0.4	4
52	Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts. BMC Neurology, 2017, 17, 110.	0.8	13
53	Evolving Failures in the Delivery of Human Immunodeficiency Virus Care: Lessons From a Ugandan Meningitis Cohort 2006–2016. Open Forum Infectious Diseases, 2017, 4, ofx077.	0.4	14
54	Evaluation of trypan blue stain in a haemocytometer for rapid detection of cerebrospinal fluid sterility in HIV patients with cryptococcal meningitis. BMC Microbiology, 2017, 17, 182.	1.3	8

#	Article	IF	CITATIONS
55	Sertraline for HIV-associated cryptococcal meningitis – Authors' reply. Lancet Infectious Diseases, The, 2016, 16, 1111-1112.	4.6	2
56	Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen Shedding. Open Forum Infectious Diseases, 2016, 3, ofv194.	0.4	18
57	Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis. Medical Mycology, 2016, 54, 361-369.	0.3	38
58	Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infectious Diseases, The, 2016, 16, 809-818.	4.6	161
59	Diagnostic performance of a multiplex PCR assay for meningitis in an HIV-infected population in Uganda. Diagnostic Microbiology and Infectious Disease, 2016, 84, 268-273.	0.8	92
60	Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis. Open Forum Infectious Diseases, 2015, 2, ofv157.	0.4	22
61	Epidemiology of Meningitis in an HIV-Infected Ugandan Cohort. American Journal of Tropical Medicine and Hygiene, 2015, 92, 274-279.	0.6	60
62	1,3-Î <sup>2</sup> -D-glucan in cryptococcal meningitis. Lancet Infectious Diseases, The, 2015, 15, 1136-1137.	4.6	11
63	Cryptococcal Meningitis: Diagnosis and Management Update. Current Tropical Medicine Reports, 2015, 2, 90-99.	1.6	123
64	Early ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis and Macrophage Activation in a Multisite Randomized Trial. Journal of Infectious Diseases, 2015, 212, 769-778.	1.9	60
65	Evaluation of Fingerstick Cryptococcal Antigen Lateral Flow Assay in HIV-Infected Persons: A Diagnostic Accuracy Study: Figure 1 Clinical Infectious Diseases, 2015, 61, 464-467.	2.9	81
66	1432Diagnostic Performance of a Multiplex PCR Assay for Meningitis in an HIV-Infected Population in Uganda. Open Forum Infectious Diseases, 2014, 1, S377-S377.	0.4	2
67	Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited Settings. Open Forum Infectious Diseases, 2014, 1, ofu070.	0.4	36
68	Detection of High Cerebrospinal Fluid Levels of (1â†'3)-β-d-Glucan in Cryptococcal Meningitis. Open Forum Infectious Diseases, 2014, 1, ofu105.	0.4	35
69	The Effect of Therapeutic Lumbar Punctures on Acute Mortality From Cryptococcal Meningitis. Clinical Infectious Diseases, 2014, 59, 1607-1614.	2.9	145
70	Accuracy of Noninvasive Intraocular Pressure or Optic Nerve Sheath Diameter Measurements for Predicting Elevated Intracranial Pressure in Cryptococcal Meningitis. Open Forum Infectious Diseases, 2014, 1, ofu093.	0.4	34
71	Central nervous system cryptococcoma in a Ugandan patient with Human Immunodeficiency Virus. Medical Mycology Case Reports, 2014, 6, 10-13.	0.7	11
72	Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis. New England Journal of Medicine, 2014, 370, 2487-2498.	13.9	387

#	Article	IF	CITATIONS
73	Unmasking cryptococcal meningitis immune reconstitution inflammatory syndrome in pregnancy induced by HIV antiretroviral therapy with postpartum paradoxical exacerbation. Medical Mycology Case Reports, 2014, 5, 16-19.	0.7	14
74	Diagnosis and Management of Cryptococcal Relapse. Journal of AIDS & Clinical Research, 2013, 01, .	0.5	42
75	Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study. PLoS Medicine, 2010, 7, e1000384.	3.9	245
76	Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, 1694-1701.	2.9	278
77	The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis. Wellcome Open Research, 0, 6, 45.	0.9	3
78	Can improved diagnostics reduce mortality from Tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. Wellcome Open Research, 0, 3, 64.	0.9	5